JP2021502382A - 経口リファマイシンｓｖ組成物 - Google Patents

経口リファマイシンｓｖ組成物 Download PDF

Info

Publication number
JP2021502382A
JP2021502382A JP2020526001A JP2020526001A JP2021502382A JP 2021502382 A JP2021502382 A JP 2021502382A JP 2020526001 A JP2020526001 A JP 2020526001A JP 2020526001 A JP2020526001 A JP 2020526001A JP 2021502382 A JP2021502382 A JP 2021502382A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
oral pharmaceutical
rifamycin
composition according
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020526001A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502382A5 (https=
Inventor
モロ ルイジ
モロ ルイジ
マリア ロンゴ ルイージ
マリア ロンゴ ルイージ
Original Assignee
コスモ・テクノロジーズ・リミテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コスモ・テクノロジーズ・リミテツド filed Critical コスモ・テクノロジーズ・リミテツド
Publication of JP2021502382A publication Critical patent/JP2021502382A/ja
Publication of JP2021502382A5 publication Critical patent/JP2021502382A5/ja
Priority to JP2023101775A priority Critical patent/JP7651620B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2020526001A 2017-11-10 2018-11-07 経口リファマイシンｓｖ組成物 Pending JP2021502382A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023101775A JP7651620B2 (ja) 2017-11-10 2023-06-21 経口リファマイシンｓｖ組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762584226P 2017-11-10 2017-11-10
US62/584,226 2017-11-10
PCT/IB2018/058748 WO2019092614A1 (en) 2017-11-10 2018-11-07 Oral rifamycin sv compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023101775A Division JP7651620B2 (ja) 2017-11-10 2023-06-21 経口リファマイシンｓｖ組成物

Publications (2)

Publication Number Publication Date
JP2021502382A true JP2021502382A (ja) 2021-01-28
JP2021502382A5 JP2021502382A5 (https=) 2021-11-18

Family

ID=64426987

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020526001A Pending JP2021502382A (ja) 2017-11-10 2018-11-07 経口リファマイシンｓｖ組成物
JP2023101775A Active JP7651620B2 (ja) 2017-11-10 2023-06-21 経口リファマイシンｓｖ組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023101775A Active JP7651620B2 (ja) 2017-11-10 2023-06-21 経口リファマイシンｓｖ組成物

Country Status (17)

Country Link
US (3) US11564883B2 (https=)
EP (3) EP4438039A3 (https=)
JP (2) JP2021502382A (https=)
KR (1) KR102747348B1 (https=)
CN (1) CN111328279B (https=)
AR (1) AR114140A1 (https=)
AU (1) AU2018364617B2 (https=)
BR (1) BR112020009171A2 (https=)
CA (1) CA3078900A1 (https=)
DK (1) DK3706724T3 (https=)
ES (1) ES2989706T3 (https=)
FI (1) FI3706724T3 (https=)
IL (1) IL274414B2 (https=)
MX (1) MX2020004706A (https=)
PL (1) PL3706724T3 (https=)
WO (1) WO2019092614A1 (https=)
ZA (1) ZA202002726B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022102198A (ja) * 2020-12-25 2022-07-07 ライオン株式会社 内服固形剤
US20220280478A1 (en) * 2021-03-05 2022-09-08 Bausch Health Ireland, Limited Methods of using rifamycin sv for the treatment of sickle cell disease
EP4412588A1 (en) * 2021-10-05 2024-08-14 Cosmo Technologies Ltd An in-situ gelling enema of rifamycin for treating pouchitis and distal ulcerative colitis
WO2025064599A1 (en) * 2023-09-19 2025-03-27 The United States Government As Represented By The Department Of Veterans Affairs Rifamycin composition for treating sarcopenia
WO2025157240A1 (zh) * 2024-01-26 2025-07-31 丹诺医药（苏州）股份有限公司 化合物用于制备治疗细菌代谢相关疾病的药物的用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003501457A (ja) * 1999-06-14 2003-01-14 コスモ ソシエタ ペル アチオニ 制御放出および味感遮蔽経口医薬組成物
WO2007077893A1 (ja) * 2006-01-04 2007-07-12 National University Corporation, Tokyo Medical And Dental University 肝臓疾患治療剤及び肝機能改善剤
JP2008503540A (ja) * 2004-06-25 2008-02-07 コスモ・テクノロジーズ・リミテツド 経口抗菌医薬組成物
JP2012504649A (ja) * 2008-10-02 2012-02-23 サリックス ファーマシューティカルズ リミテッド 肝性脳症を治療する方法
JP2015506999A (ja) * 2012-02-13 2015-03-05 コスモ・テクノロジーズ・リミテツド 少なくとも１つの炎症性要素を呈する腸管疾患を治療するための方法
JP2017520624A (ja) * 2014-06-30 2017-07-27 サリックス ファーマスーティカルズ，インコーポレーテッド 過敏性腸症候群（ｉｂｓ）を再治療するための方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
WO2005030173A1 (en) 2003-09-25 2005-04-07 Ranbaxy Laboratories Limited Colon-specific drug delivery using interpolymer complexations
BRPI0908026B8 (pt) 2008-02-26 2021-05-25 Salix Pharmaceuticals Ltd uso de rifaximina no tratamento de doenças do intestino
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US8741048B2 (en) 2011-08-30 2014-06-03 Brother Kogyo Kabushiki Kaisha Water-based ink for ink-jet recording and ink cartridge
WO2017053885A1 (en) * 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003501457A (ja) * 1999-06-14 2003-01-14 コスモ ソシエタ ペル アチオニ 制御放出および味感遮蔽経口医薬組成物
JP2008503540A (ja) * 2004-06-25 2008-02-07 コスモ・テクノロジーズ・リミテツド 経口抗菌医薬組成物
WO2007077893A1 (ja) * 2006-01-04 2007-07-12 National University Corporation, Tokyo Medical And Dental University 肝臓疾患治療剤及び肝機能改善剤
JP2012504649A (ja) * 2008-10-02 2012-02-23 サリックス ファーマシューティカルズ リミテッド 肝性脳症を治療する方法
JP2015506999A (ja) * 2012-02-13 2015-03-05 コスモ・テクノロジーズ・リミテツド 少なくとも１つの炎症性要素を呈する腸管疾患を治療するための方法
JP2017520624A (ja) * 2014-06-30 2017-07-27 サリックス ファーマスーティカルズ，インコーポレーテッド 過敏性腸症候群（ｉｂｓ）を再治療するための方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. Vol.55, pp.2122-2128, JPN6022037968, 2011, ISSN: 0004995558 *
CLINICAL TRIALS, 'RIFAMYCIN SV-MMX 600 MG TABLETS ADMINISTERED THREE OR TWO TIMES DAILY TO PATIENTS, JPN6022037967, March 2017 (2017-03-01), ISSN: 0004995557 *
EXPERT OPINION ON PHARMACOTHERAPY, vol. Vol.18, No.12, pp.1269-1277, JPN6022037970, 2017, ISSN: 0004995559 *
診断と治療, vol. Vol.103, No.8, pp.1041-1045, JPN6022037971, 2015, ISSN: 0004995560 *

Also Published As

Publication number Publication date
AR114140A1 (es) 2020-07-29
PL3706724T3 (pl) 2024-12-16
AU2018364617B2 (en) 2024-11-07
KR20200086285A (ko) 2020-07-16
EP4438039A3 (en) 2024-12-04
MX2020004706A (es) 2020-09-07
RU2020119035A (ru) 2021-12-10
ES2989706T3 (es) 2024-11-27
WO2019092614A1 (en) 2019-05-16
US12036316B2 (en) 2024-07-16
IL274414B2 (en) 2024-08-01
CN111328279B (zh) 2023-04-14
CN111328279A (zh) 2020-06-23
US11564883B2 (en) 2023-01-31
CA3078900A1 (en) 2019-05-16
US20240398699A1 (en) 2024-12-05
DK3706724T3 (da) 2024-10-14
EP4431094A3 (en) 2024-11-20
EP3706724B1 (en) 2024-09-11
IL274414B1 (en) 2024-04-01
JP2023112076A (ja) 2023-08-10
ZA202002726B (en) 2024-09-25
FI3706724T3 (fi) 2024-10-14
AU2018364617A1 (en) 2020-05-07
EP3706724A1 (en) 2020-09-16
IL274414A (en) 2020-06-30
US20200281850A1 (en) 2020-09-10
RU2020119035A3 (https=) 2022-04-20
JP7651620B2 (ja) 2025-03-26
KR102747348B1 (ko) 2024-12-31
BR112020009171A2 (pt) 2020-11-03
EP4431094A2 (en) 2024-09-18
US20230135346A1 (en) 2023-05-04
EP4438039A2 (en) 2024-10-02

Similar Documents

Publication Publication Date Title
JP7651620B2 (ja) 経口リファマイシンｓｖ組成物
US20130259906A1 (en) Pharmaceutical composition comprising one or more fumaric acid esters
JP2009537547A (ja) 生物学的治療組成物およびその使用
US20180200308A1 (en) Methods of treating colitis
KR20150132214A (ko) 방사선 직장ｓ상결장염의 치료를 위한 조성물 및 방법
CN108289870A (zh) 治疗特定患者群体的神经变性病症的方法
CA2918004C (en) A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
TW202203934A (zh) 治療涉及全身過度發炎性反應的病症的受體相互作用蛋白激酶抑制劑
RU2793319C2 (ru) Композиции рифамицина sv для перорального применения
HK40110949A (en) Oral rifamycin sv compositions
HK40110239A (en) Oral rifamycin sv compositions
HK40036103A (en) Oral rifamycin sv compositions
HK40036103B (en) Oral rifamycin sv compositions
JP2016515602A (ja) Ｉｂｄの治療に使用するためのミルテホシンまたはペリホシン
US20140322313A1 (en) Pharmaceutical compositions of ibuprofen and an h2 receptor antagonist
KR20260021653A (ko) IgA 매개 질환의 치료 방법에 사용하기 위한 스파르센탄
Tolentino-Hernández et al. Bioequivalence of Two Oral Ciprofloxacin Extended-Release Formulations in Healthy Mexican Volunteers
RU2690372C2 (ru) Лекарственные средства, содержащие диацереин, и способы снижения уровней мочевой кислоты в крови с его использованием
HK1250932A1 (en) Formulations containing diacerein and methods of lowering blood levels of uric acid using the same
MXPA05009025A (es) Agentes de tratamiento para el sindrome de intestino delgado irritado con diarrea predominante.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211008

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211008

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230221